Elacestrant: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and NICE (England), among others, recommended or restricted elacestrant, while PBAC (Australia) and SMC (Scotland) did not recommend it.
The record spans 2.2 years, opening at G-BA (Germany) on 2 May 2024 and running to 2026.
CIPM (Spain) changed its position: not recommended on 26 Mar 2025, recommended by 28 Apr 2026, after a resubmission.
No assessment is on file from PHARMAC (New Zealand) and TLV (Sweden), each among the eight highest-volume agencies here.
The file is active: 12 of 14 records date from 2023 or later.
Against its own class, elacestrant is an outlier: 45% of its decisive outcomes were positive, where molecules sharing ATC class L02B average 78%.
5 distinct indication wordings are recorded for elacestrant by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 14 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
G-BA (Germany) was first to assess elacestrant, on 2 May 2024; NYE METODER (Norway) did not open a file until 14 Jun 2026 — a moderate spread of 2.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 12 dated records fall in 2025 alone.
2 of the 10 agencies here assessed elacestrant more than once, CIPM (Spain) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
10 of the 18 agencies in this archive hold a record for elacestrant.
The full ledger for elacestrant reads 6 not recommended, 4 recommended, 1 no benefit and 1 restricted, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 14 Jun 2026 | Monoterapi til behandling av postmenopausale kvinner, og menn, med østrogenreseptor (ER)-positiv, HER2-negativ, lokalt a… | introduced | source |
| CIPM (Spain) | 25 Feb 2026 | Indicaciones terapéuticas autorizadas: ORSERDU en monoterapia está indicado para el tratamiento de hombres y mujeres pos… | not financed by the SNS (financed 2026-04) | source |
| SMC (Scotland) | 10 Nov 2025 | Treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 muta… | not recommended | source |
| PBAC (Australia) | 2025 | Estrogen receptor-positive (ER+) human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer | Not Recommended | source |
| AIFA (Italy) | 19 May 2025 | Orserdu in monoterapia è indicato per il trattamento di donne in postmenopausa, e di uomini, con carcinoma mammario loca… | innovative status not granted · reimbursed class H | source |
9 further decisions for elacestrant, across 7 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 8 further source documents.
Related molecules
- enzalutamide — same ATC class L02B — Endocrine therapy
- darolutamide — same ATC class L02B — Endocrine therapy
- apalutamide — same ATC class L02B — Endocrine therapy
- abiraterone — same ATC class L02B — Endocrine therapy
- fulvestrant — same ATC class L02B — Endocrine therapy
- relugolix — same ATC class L02B — Endocrine therapy
Coverage: 14 decisions for elacestrant from 10 agencies, 2024 to 2026. Data to 7 Sep 2026. ATC class L02B — Endocrine therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.